Worsened Disease Progression and Relapse Rate in MOGAD Are Predicted by Non-P42 MOG-IgG Serotype.

Published Date: 08 Feb 2024

In MOGAD, patients with non-P42 MOG-IgG had a relapse course risk that was more than three times higher than that of patients with P42 MOG-IgG.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot